Together,
we are changing
the future

Avellino, a leader in precision medicine, is making a global impact in genetics and bringing innovative diagnostics, therapies, and AI-driven data processing to patient care.

AvaGen is the the first and leading personalized genetic eye test. AvaGen quantifies the risk or presence of keratoconus and other corneal genetic disorders caused by gene variants.

The Avellino SARS-CoV-2/COVID-19 Test (AvellinoCoV2) is a non-invasive, swab based test used to detect the SARS-CoV-2 virus.

A global leader in precision medicine, gene therapy and molecular diagnostics

Our mission is to bring personalized medicine to eyecare professionals by delivering actionable information derived from the unique genes of individual patients.

Collabration help us aim higher

Avellino collaborates with best-in-class partners to create first-in-class genetic tests and gene-editing therapies. These collaborations provide the chance to integrate precision medicine into existing healthcare practices and ultimately improve them.

Transforming data into action

Data must be straightforward for precision medicine to be properly integrated into clinical care. Avellino provides multiple layers of support in the patient treatment process to assist the clinician with interpreting results, explaining results to patients, delivering personalized treatment, and improving patient outcomes

Precision medicine starting with the eye

At its very core, precision medicine begins with genetics. Tailoring treatment relies on recognizing individual characteristics and a patient’s unique susceptibility to certain diseases. For Avellino, providing real genetic data that correlate with those susceptibilities is the key.

Where to next?

Avellino is building upon the success of its own proprietary Universal test, the world’s first DNA test confirming the presence of genetic indicators positively associated with corneal dystrophies. Our latest preemptive diagnostic tool, AvaGen, addresses keratoconus in addition to corneal dystrophies, and is set to expand to address Fuchs’ dystrophy, glaucoma, and a wide range of other eye diseases in the near future.